The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction*
Abstract
OBJECTIVE: Cardiogenic shock is the leading cause of death in patients hospitalized for acute myocardial infarction. The objectives were to investigate the effects of levosimendan, a novel inodilator, compared with the phosphodiesterase-III inhibitor enoximone in refractory cardiogenic shock complicating acute myocardial infarction, on top of current therapy. DESIGN: Prospective, randomized, controlled single-center clinical trial. SETTING: Medical and coronary intensive care unit in a university hospital. PATIENTS: Thirty-two patients with refractory cardiogenic shock for at least 2 hrs requiring additional therapy. INTERVENTIONS: Infusion of either levosimendan (12 microg/kg over 10 min, followed by 0.1 microg/kg/min over 50 min, and of 0.2 microg/kg/min for the next 23 hrs) or enoximone (fractional loading dose of 0.5 mg/kg, followed by 2-10 microg/kg/min continuously) after initiation of current therapy, always including revascularization, intra-aortic balloon pump counterpulsation, and inotropes. MEASUREMENTS AND MAIN RESULTS: Survival rate at 30 days was significantly higher in the levosimendan-treated group (69%, 11 of 16) compared with the enoximone group (37%, 6 of 16, p = 0.023). Invasive hemodynamic parameters during the first 48 hrs were comparable in both groups. Levosimendan induced a trend toward higher cardiac index, cardiac power index, left ventricular stroke work index, and mixed venous oxygen saturation. In addition, lower cumulative values for catecholamines at 72 hrs and for clinical signs of inflammation were seen in the levosimendan-treated patients. Multiple organ failure leading to death occurred exclusively in the enoximone group (4 of 16 patients). CONCLUSIONS: In severe and refractory cardiogenic shock complicating acute myocardial infarction, levosimendan, added to current therapy, may contribute to improved survival compared with enoximone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Group sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
van Diepen, S., Katz, J. N., Albert, N. M., Henry, T. D., Jacobs, A. K., Kapur, N. K., Kilic, A., Menon, V., Ohman, E. M., Sweitzer, N. K., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000525 · Cited by 1,869
Management of cardiogenic shock complicating myocardial infarction: an update 2019
Thiele, H., Ohman, E. M., de Waha-Thiele, S., Zeymer, U., & Desch, S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz363 · Cited by 683
Metadata
- Authors
- Fuhrmann, J. T., Schmeisser, A., Schulze, M. R., Wunderlich, C., Schoen, S. P., Rauwolf, T., Weinbrenner, C., & Strasser, R. H.
- Venue
- Critical Care Medicine
- Published
- 2008-08
- Volume
- 36
- Issue
- 8
- Pages
- 2257-2266
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2057328088
- Cited by
- 202
- References
- 1
- FWCI
- 9.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction*. https://app.cochat.ai/papers/10.1097/ccm.0b013e3181809846
- The paper
- Fuhrmann, J. T., Schmeisser, A., Schulze, M. R., Wunderlich, C., Schoen, S. P., Rauwolf, T., Weinbrenner, C., & Strasser, R. H. (2008). Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction*. Critical Care Medicine. https://doi.org/10.1097/ccm.0b013e3181809846
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.